Mobile website
Archive > Volume 24 Issue 11 > 2017,24(11):1287-1292. DOI:10.3872/j.issn.1007-385X.2017.11.008 Prev Next
Clinical Research
Expression of human interleukin 11 in DLBCL and its relevance to thrombocytopenia of the patients with DLBCL after chemotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To detect expression of human interleukin 11 (IL-11) gene in tissue and blood specimens of the patients with diffuse large B-cell lymphoma (DLBCL), and to explore the relationship between expression of IL-11 gene and prognosis of the patients with DLBCL as well as its effect on thrombocytopenia of the patients with DLBCL after chemotherapy. Methods: Tissue and blood specimens of 88 patients with DLBCL and 42 patients with reactive lymphoid hyperplasia (RLH) who were made a definite diagnosis in Department of Hematology, the First Hospital of Handan City of Hebei Province during January 2012 to December 2016 were collected. qPCR was used to detect expression of IL-11 in the tumor tissues and blood specimens. Univariate and multivariate Cox regression analyses were used to analyze relationship of IL-11 expression in the tissues with clinical pathological features and prognosis of the patients with DLBCL as well as independent factors effecting prognosis of the patients. Correlationship between expression of IL-11 and thrombocytopenia after chemotherapy in the patients with DLBCL was analyzed,as wall as relationships of the IL-11 expression with overall survival (OS) and progression free survival (PFS)were analyzed by Kaplan-Meier assay. Results: Comparing with the patients with RLH in control group, expressions of IL-11 in tissue and blood of the patients with DLBCL were significant higher (in tissue: 7.002±0.357 vs 1.507±0.139; in blood: 6.700±0.337 vs 1.446±0.126, all P<0.01). In the patients with DLBCL, expression of IL-11 was correlated to tumor size, clinical staging, B cell symptom, sensitivity of chemotherapy and IPI index (all P<0.01). OS and PFS of the patients with high expression of IL-11 were shorter than those of the patients with low expression of IL-11 (all P<0.01). Expression of IL-11, sensitivity of chemotherapy and IPI index were independent factors affecting prognosis of the patients with DLBCL. In the patients with thrombocytopenia after chemotherapy, expression of IL-11 in serum and platelet count were negative correlated(r=-0.732, P<0.01). Conclusion: IL-11 was highly expressed in tissue and blood of the patients with DLBCL. OS and PFS of the DLBCL patients with high expression of IL-11 were significantly shortened, in whom, platelet severely reduced after chemotherapy. IL-11 might be expected to become an independent biological marker which could judge prognosis of the patients with DLBCL.
Keywords:
Project Supported:
Clc Number:
